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Immunogold electron microscopyNitric oxide synthase (NOS) expression and catalytic status in human peripheral blood mononuclear cells
(PBMCs) is debatable, while its sub-cellular distribution remains unascertained. The present study
characterizes NOS transcripts by real time PCR, NOS protein by immunoprecipitation (IP)/Western blot
(WB), nitric oxide (NO) generation by DAF-2DA and NOS sub-cellular distribution by immunogold electron
microscopy in resting PBMCs, monocytes and lymphocytes obtained from healthy donors. We observed
constitutive expression of full length NOS isoforms (nNOS, iNOS and eNOS) in PBMCs: with the highest
expression of iNOS in comparison to nNOS and eNOS. Isolatedmonocytes expressedmore eNOS transcript and
protein as compared to nNOS and iNOS. Lymphocytes however had more iNOS transcripts and protein than
nNOS and eNOS. NOS was catalytically active in PBMCs, monocytes as well as in lymphocytes as evident by NO
generation in the presence of substrate and cofactors, which was signiﬁcantly reduced in the presence of NOS
inhibitor. Immunogold electron microscopy and morphometric analysis revealed the distinct pattern of NOS
distribution in monocytes and lymphocytes and also exhibited differences in the nuclear–cytoplasmic ratio.
nNOS localization wasmuchmore in the cytosol than in the nucleus among bothmonocytes and lymphocytes.
Interestingly, iNOS distribution was comparable in both cytosol and nucleus among monocytes, but in
lymphocytes iNOS was predominantly localized to the cytosol. The present study exhibits constitutive
presence of all the NOS isoforms in PBMCs and reports the distinct pattern of NOS distribution among
monocytes and lymphocytes.entral Drug Research Institute
411 18x4254; fax: +91 522
hit).
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Nitric oxide (NO) is generated by the blood cells including PBMCs
which regulates vascular hemostasis, peripheral immune response
and hematopoiesis, by modulating signaling, gene expression and the
balance between proliferation and differentiation [1–3]. Beneﬁcial
and cytotoxic actions of NO have been correlated with its concentra-
tion/availability [4–6]. There is a dearth of studies regarding NOS
localization in PBMCs, while contradictions exist on the ability of
PBMCs to generate NO, NOS expression and the presence [7–10] or
absence [11–13] of NOS protein among PBMCs. It was demonstrated
that as compared to murine macrophages, humanmacrophages failed
to secrete NO (b0.1 μmol/106 cells/24 h), even after treatment with
endotoxin, interferon-gamma, granulocyte–macrophage colony-stimulating factor, tumor necrosis factor-alpha, bacteria, or prolifer-
ating lymphocytes [13].
Expression of both cNOS and iNOS has been reported among
PBMCs at transcript and/or protein level by using different experi-
mental approaches. Constitutive expression of iNOS was detected by
RT-PCR and Northern blot analysis in monocytes of control subjects
but could not be conﬁrmed byWestern blot analysis [7]. The presence
of eNOS transcript was also demonstrated in IgD+ or IgD− B cells,
peripheral blood, tonsillar T cells and in circulating monocytes [8].
However, the quantitative expression of NOS isoforms at mRNA and
protein levels in monocytes and lymphocytes has not been well
explored. NOS activity could not be measured in sub-cellular fractions
of human macrophages even after tetrahydrobiopterin (BH4) supple-
mentation [13]. Others have also dissociated NO generation from the
microbicidal actions of monocytic phagocytes [11,12]. These reports
are contrary to those advocating expression of NOS and NO pro-
duction from the PBMCs [7–10]. Thus biochemical and molecular
characterization of the NOS system in PBMCs needs to be explored in a
systematic manner.
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might be modulated by post-translational regulations imposed on
NOS even after genetic check points have been passed. The
microenvironment inside sub-cellular organelles harboring NOS
may inﬂuence catalysis through variations in pH, co-factor and
substrate availability, or by interaction with regulatory protein
partners to either promote or impede catalysis while in association
with NOS. Distinct sub-cellular distribution of various NOS isoforms
might affect their catalytic potential and modulate organelle speciﬁc
as well as overall cellular functions. Analyzing the intracellular
localization of NOS [14–20] thus may facilitate our understanding of
cell physiology and be an informative tool for the studies related to NO
generation, nitrosylation of signaling proteins and trafﬁcking of
certain cargo proteins [4,21,22]. Studies exploring NOS localization
in neutrophils [23], endothelial cells [24], astrocytes [20], adipocytes
[15], and eosinophils [25] have highlighted the importance of NOS
distribution/trafﬁcking to various intracellular compartments, which
is unexplored in PBMCs. The present study was therefore undertaken
to systematically identify and quantify the NOS isoforms at mRNA and
protein level as well as to assess the NO generation in resting PBMCs,
and in isolated monocytes and lymphocytes. Moreover, we have
further extended this study to demonstrate the relative sub-cellular
distribution pattern of NOS isoforms in PBMCs obtained from healthy
human volunteers.
2. Materials and methods
2.1. Reagents and antibodies
RevertAid™ H Minus First Strand cDNA synthesis kit and 2× SYBR
green PCR master mix were procured from Fermentas. L- [3H]
arginine, 10 nm and 15 nm gold conjugated goat anti-mouse and
goat anti-rabbit antibodies were purchased from Amersham Bio-
sciences (Sweden). Uranyl acetate was obtained from Polaron
Equipment Ltd. (England). Antibodies against human nNOS (rabbit
polyclonal), iNOS (mouse monoclonal) and goat anti-rabbit IgG HRP
were from Santa Cruz (USA). Immunoprecipitation starter pack was
purchased from GE Healthcare (USA). Monoclonal antibody against
human eNOS (mouse monoclonal) and all other chemicals were
procured from Sigma Aldrich Co. (USA).
2.2. Human subjects
Blood was collected in citrate–phosphate–dextrose (CPD) (1:7)
from healthy volunteers. A detailed medical history and physical
examination was carried out before phlebotomy. The donors were
free from heart, lung and kidney diseases, cancer, epilepsy, diabetes,
tuberculosis, abnormal bleeding tendency, allergic disease, sexually
transmitted diseases, jaundice, malaria, typhoid and thyroid/or any
other endocrine disorders. Donors were also free from any prior
medication for the last 72 h before sample collection. The study was
performed in accordance with guidelines set by the ethical committee
of the institute.
2.3. Isolation of peripheral blood mononuclear cells (PBMCs), monocytes
and lymphocytes
Peripheral blood mononuclear cells (PBMCs) were isolated by
loading diluted blood (1:1 with saline) on Histopaque 1077 and
centrifuged at 400 g for 30 min at 20 °C (3 K30 Sigma Centrifuge,
Germany) [26]. PBMCs collected from the interface were washed
twice with Hank's Balanced Salt Solution (HBSS) by centrifugation at
100 g for 10 min at 20 °C and re-suspended in RPMI 1640 and were
cultured for 2 h[27]. All the steps were carried out under sterile
conditions. Adhered monocytes and ﬂoated lymphocytes were
collected for subsequent analysis. The purity of the isolated mono-cytes and lymphocytes was assessed by using CD14 and CD3
antibodies in a ﬂow cytometer (FACS Calibur, Becton Dickinson,
USA) and was found more than 94% and 95% respectively. Viability of
the isolated blood cells was also more than 90% as assessed by Trypan
blue exclusion test.
2.4. NOS transcripts by quantitative (real-time PCR)
Total RNA was isolated from human PBMCs lymphocytes and
monocytes using Tri reagent (Sigma, USA). 5 μg of total RNA was
reverse transcribed with RevertAid™ H Minus First Strand cDNA
Synthesis Kit (Fermentas) using oligo (dT) primers, as per the
manufacturer's instructions. The cDNA was ampliﬁed in PCRs by
using primers for neuronal NOS (F-5′TCTAACAGGCTGGCAATGAAG3′,
R-5′TCTCTAAGGAAGTGATGGTTGAC3′), inducible NOS (F-5′
GTTCTCAAGGCACAGGTCTC3′, R-5′GCAGGTCACTTATGT CACTTATC3′)
endothelial NOS (F-5′ATTATATCCTACACAAGACTCCAG3′, R-5′
TCTTCAAGTTGCCCATGTTAC3′) [28] and β-actin (F-5′AACT
GGAACGGTGAAGGTG3′, R-5′CTGTGTGGACTTGGGAGAGG3′) [29],
which ampliﬁed 165 bp, 210 bp, 160 bp and 208 bp products
respectively. Real-time RT-PCR was performed with a Maxima SYBR
Green RT-PCR Kit (Fermentas) on Roche light cycler. Reaction volume
was 25 μl volumes, which included 12.5 μl of 2× Maxima SYBR Green
RT-PCR Master Mix, 1 μl cDNA template, and 0.2 μmol/l primers
designed to amplify a part of each gene. Three-step PCR protocol
applied for nNOS reactions consisted of 35 cycles of 95 °C for 15 s,
57 °C for 30 s, and 72 °C for 30 s, for iNOS of 35 cycles of 95 °C for 15 s,
55 °C for 30 s, and 72 °C for 30 s, and for eNOS of 35 cycles of 95 °C for
15 s, 56 °C for 30 s, and 72 °C for 30 s. After PCR, a melting curve
analysis consisting of 1 cycle: 95 °C for 0 s, 70 °C for 10 s, 95 °C for 0 s,
cooling 1 cycle: 40 °C for 3 min was performed to demonstrate the
speciﬁcity of the PCR product as a single peak. The ampliﬁcation
reactions for β-actin were 30 cycles of 95 °C for 15 s, 55 °C for 30 s,
and 72 °C for 30 s. The differences in the threshold cycles for β-actin
and NOS isoforms were used to calculate the expression levels of NOS
mRNA.
2.5. NOS immunoprecipitation and Western blotting
PBMCs, monocytes and lymphocytes were suspended in ice-cold
radio IP assay (RIPA) buffer [PBS containing 1 mM EDTA, 1 mM
sodium orthovanadate, 1 mM sodium ﬂuoride, 1 μg/ml aprotinin,
100 μg/ml PMSF, 20 μg/ml pepstatin, 5 mM di-isopropyl ﬂuoropho-
sphates (DFP)] were lysed with 1% Triton X 100 and 0.1% SDS at 4 °C,
and were exposed to rabbit IgG (1 μg for nNOS and eNOS) and mouse
IgG (1 μg for iNOS) for 1 h at 4 °C and then ‘precleared’ using protein-
G agarose beads. Following centrifugation, the supernatant was
collected and incubated with 1 μg of nNOS, iNOS or eNOS antibodies
[23]. Western blotting (WB) was performed with primary (at 1:500
in 1.5% skimmed milk TBST) and HRP-conjugated anti-rabbit IgG
(for nNOS) or anti-mouse (for iNOS and eNOS) secondary antibodies
(at 1:20,000 in 1.5% skimmed milk TBST) followed by chemilumines-
cence detection (Millipore, USA). β-actin was used to normalize the
NOS expression, which was assessed in the protein sample at 1:25
dilution. It was done to avoid the dispersion of the band which
otherwise would hinder in densitometry analysis. NOS immunopre-
cipitation was performed in the undiluted sample.
2.6. NO generation by ﬂow cytometry
NO production in human PBMCs, monocytes and lymphocytes was
assessed in the presence or absence of NOS cofactors (BH4, 10 μM,
NADPH 1 mM, FAD 5 μM, FMN 25 μM, L-Arg 0.15 μM, ascorbate 1 mM)
and NOS inhibitor (L-NAME 10 μM), using DAF-2DA (10 μM), a NO
probe by ﬂow cytometry [30]. DAF, yields a green ﬂuorescent triazole
(DAF-2T) following binding toNO, offering the advantage of speciﬁcity
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acquired using a ﬂow cytometer (FACS Calibur, Becton Dickinson, USA)
and analyzed by Cell Quest program. Cells without DAF-2DA treatment
were used as negative control, and NO generation potential was
assessed by comparing the cells in the presence and absence of L-NAME.2.7. NOS catalytic activity in PBMCs
PBMCs suspended in incubationbuffer (Hepes 25 mM;NaCl 140 mM;
KCl 5.4 mM; MgCl2 1 mM; pH 7.4) were sonicated and incubated with
tetrahydrobiopterin (BH4) (100 μM), NADPH (1mM), FAD (5 μM), FMN
(25 μM), and calmodulin (10 μg/ml) in the presence of CaCl2 (2 mM) or
EGTA (5 mM). Reaction was initiated by adding L-[3H] arginine,
continued for 30 min at 37 °C and was stopped by adding ice-cold stop
buffer (NaCl, 118 mM; KCl, 4.7 mM; KH2PO4, 1.18 mM; NaHCO3, 1 mM;
EDTA, 4 mM; Nω-Nitro-L-arginine methyl ester (L-NAME), 5 mM; pH
5.5). The reaction mixture was passed through Dowex 50WX8-400
columns. Radioactivity in the eluent was measured using β-scintillation
counter (LKB Wallace 1409, Liquid Scintillation counter, USA) as
described elsewhere [23]. Calcium independent activity was evaluated
in the presence of EGTA (5 mM). Calcium dependent NOS catalysis was
evaluated in the presence of CaCl2 (2 mM). NOS catalysis has been
reported as pmol of L-[3H] citrulline formed/30 min/107 cells.2.8. Immunogold electron microscopy
Buffy coat obtained after centrifugation of human blood at 800 g
for 20 min at 25 °C (3 K30 Sigma Centrifuge, Germany), was ﬁxed
overnight at 25 °C with 2% (w/v) paraformaldehyde and 0.5% (v/v)
glutaraldehyde in PBS (pH 7.4) at 25 °C. Small pieces of buffy coat
washed with PBS containing 0.5% (w/v) glycine to quench excess
ﬁxative were dehydrated in an ascending series of ethanol (30% for
30 min, 50% for 30 min, 70% for 30 min, 90% for 1 h, absolute alcohol
for 1 h), impregnated in London–White resin, and polymerized at
60 °C for 48 h. Ultrathin sections (80–100 nm) collected on nickel
grids were blocked in PBS containing 0.1% BSA (w/v) and 1% (v/v)
Teleost ﬁsh gelatin for 30 min at room temperature and incubated
overnight with or without (for negative control) nNOS, iNOS or eNOS
antibodies at 1:200 dilution in blocking buffer at 4 °C, washed 10
times with blocking buffer and subsequently, sections were incubated
with 10 or 15 nm gold-coupled goat anti-mouse or goat anti rabbit IgG
(1:20) for 2 h at 37 °C. Grids were further washedwith blocking buffer
and then 10 times with water. The grids were stained with 1% uranyl
acetate. After washing 10 times with water grids were examined
under TEM at 80 kV [23].2.9. Morphometric analysis
The density of the gold particles in the PBMCs (both lymphocyte
and monocyte) was quantitatively evaluated after immunogold
labeling with nNOS, iNOS or eNOS antibodies and subsequently with
a secondary antibody coupled to 10 or 15 nm gold particles. The total
6 grids from three independent experiments for NOS labeling were
used for this analysis. Electron micrographs were captured at 11,000×
magniﬁcation for the morphometric analysis as has been previously
described [23,25]. Morphometric analysis with lymphocytes and
monocytes was performed only on those cells exhibiting nucleus in
the plane of the section and the relative distribution was ascertained
by counting the total number of gold particles in the nucleus,
cytoplasm and plasma membrane for both cNOS (nNOS and eNOS)
and iNOS in the lymphocytes and monocytes. The labeling density of
nNOS, iNOS and eNOS (number of gold particles/μm2) was calculated
using the Scion Image processing software 4.0.3.2 and expressed for
different subcellular compartments in monocytes and lymphocytes.2.10. Statistical analysis
Results have been expressed as mean±SEM. Statistical analysis
between two groups was performed using unpaired ‘t’ test and among
multiple groups by one-way ANOVA followed by Newman–Keul's
post analysis test. Results were considered signiﬁcant at pb0.05.
3. Results
3.1. NOS expression, and NO generation in human PBMCs, monocytes
and lymphocytes
Transcripts for NOS isoforms in the PBMCs, monocytes and
lymphocytes were identiﬁed by real time PCR which demonstrated
constitutive expression of all the three NOS isoforms (nNOS, iNOS and
eNOS) in these cells isolated from healthy individuals. Quantitative
analysis showed signiﬁcantly higher expression of iNOS transcript as
compared to nNOS (pb0.001) and eNOS (pb0.01) in PBMCs (Fig. 1A).
Relative copy number of eNOS was signiﬁcantly more as compared to
nNOS (pb0.01) and iNOS (pb0.001) in the resting monocytes
(Fig. 1D). However, relative copy number of iNOS was signiﬁcantly
higher than nNOS (pb0.001) in resting lymphocytes (Fig. 1G). These
results clearly indicate constitutive expression of cNOS (nNOS and
eNOS) and iNOS in human PBMCs, monocytes and lymphocytes. Level
of NOS was found to be 106 folds lesser than β-actin as measured by
real time PCR. Hence, the normalized values were presented in
multiples of 106.
Expression of NOS isoforms at protein level was detected by
immunoprecipitation followed by Western blotting. The presence of
nNOS (160 kDa), iNOS (130 kDa) and eNOS (130 kDa) has been
shown in PBMCs (Fig. 1B), monocytes (Fig. 1E) and lymphocytes
(Fig. 1H). Densitometric analysis showed that iNOS expression was
more than nNOS (pb0.05) and eNOS (pb0.05) (Fig. 1B), which
correlated with the relative abundance of iNOS transcript over that of
nNOS and eNOS as was observed with real time PCR in PBMCs. In
monocytes eNOS expression was more than that of nNOS (pb0.05)
(Fig. 1E). However iNOS expression was higher than nNOS (pb0.01)
in lymphocytes (Fig. 1F). Band intensity of NOS and β-actin were
compared by using 25 fold diluted protein for β-actin than NOS.
Hence, the normalized values were presented as multiple 1/25.
NO generation in PBMCs, monocytes and lymphocytes was
measured by using DAF-2DA, a NO reactive and sensitive ﬂuorescent
probe, exhibiting NO formation in the presence of substrate and
cofactors, which was signiﬁcantly inhibited by L-NAME, the NOS
inhibitor (Figs. 1C, F and I). NOS functionality, was also conﬁrmed by
using yet another method in total PBMC lysate, in the presence/
absence of calcium, NOS substrate L-3H-arginine and cofactors, so as to
assess the relative contribution of calcium independent (5 mM EGTA)
and calcium dependent NOS (2 mM CaCl2) activity by monitoring the
formation of L3H-citrulline. Despite a relative abundance of iNOS at
transcript and protein levels, both calcium dependent and indepen-
dent isoforms were equally active in PBMCs the activity being 0.22±
0.08 pmol/30 min/107 cells and 0.20±0.003 pmol/30 min/107 cells,
respectively. These results thus demonstrate that NOS isoform spe-
ciﬁc transcripts were actively and constitutively translated into NOS
proteins and were functional in the resting PBMCs, monocytes and
lymphocytes.
3.2. NOS subcellular localization by electron microscopy
Monocytes and lymphocytes were distinguished by their nuclear
morphology. Monocytes were identiﬁed on the basis of kidney/horse
shoe shaped nuclei as described by Sambuy et al. [31] and Sandborn
[32]. Lymphocytes were readily identiﬁable in the electron micro-
scope on the basis of large, round nuclei as reported by Tokuyasu et al.
[33]. NOS localization in PBMCs (lymphocytes and monocytes) was
Fig. 1. Expression of NOS isoforms and NO generation in human PBMCs, monocytes and lymphocytes. Bar diagrams in the left panel represent the real time PCR based relative copy
number of nNOS, iNOS and eNOS as the ratio of respective NOS isoforms with housekeeping gene β-actin as a multiple of 106 in PBMCs (A) monocytes (D) and lymphocytes (G). The
data is a representation of 3 independent experiments, and have been expressed as Mean±SEM (***pb0.001 for iNOS Vs nNOS, @@pb0.01 for iNOS Vs eNOS in resting
PBMCs,@@pb0.01 for eNOS Vs nNOS, ***pb0.001 for eNOS Vs iNOS in monocytes and ***pb0.001 for iNOS Vs nNOS in lymphocytes). Protein content of nNOS, iNOS and eNOS
following immunoprecipitation/Western blot in PBMCs (B), monocytes (E) and lymphocytes lysates (H) has been shown in themiddle panel. Band 1—nNOS protein at 160 kDa, band
2—iNOS protein at 130 kDa, and band 3—eNOS protein at 130 kDa. Densitometric analysis of nNOS, iNOS and eNOS protein expression in PBMCs, monocytes and lymphocytes as the
ratio of respective NOS isoforms with β actin as a multiple of 1/25. The data is a representation of 3 independent experiments, and presented as Mean±SEM (*pb0.05 for iNOS Vs
nNOS,@pb0.05 for iNOS Vs eNOS in PBMCs, *pb0.05 for eNOS Vs nNOS, in resting monocytes and **pb0.01 for iNOS Vs nNOS, in resting lymphocytes). Right panel represents
(C) histogram overlay representing NO generation (DAF-2DA) in PBMCs (1—cells, 2—L-NAME+cells, 3—cells with cofactors and substrate and 4—L-NAME+cells with cofactors and
substrate). Bar diagram representing themean stimulation index (MSI) of NO generation (DAF-2DA) inmonocytes (F) and lymphocytes (I). The data is a representation of 3 independent
experiments, and are presented asMean±SEM (***pb0.001 for cells vs cellswith cofactors and substrate,@@pb0.01 for cells with cofactors and substrate vs L-NAME+cells with cofactors
and substrate in resting monocytes and ***pb0.001 for cells vs cells with cofactors and substrate, @pb0.05 for cells with cofactors and substrate vs L-NAME+cells with cofactors and
substrate in resting lymphocytes).
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basis of the above mentioned criteria. Experiments were conducted
with speciﬁc nNOS, iNOS or eNOS antibodies. Moreover under the
same condition used, no signiﬁcant binding was observed with
isotype matched control antibodies or secondary antibody alone. The
sparse bindingwith the secondary antibody has even been subtracted,
while performing morphometric analysis to assess speciﬁc NOS
antibody binding.
3.2.1. nNOS, iNOS and eNOS localization in monocytes
Figs. 2A and B demonstrate nNOS immunolabeling in the
cytoplasm, nucleus and nuclear membrane as well as at the sites
adjacent to the plasma membrane. The presence of nNOS as dimers
and monomers were seen in the nucleus which could be suggestive of
catalytically active NOS conﬁguration (Fig. 2A). The presence of iNOSand eNOS in the cytoplasm, nucleus and nuclear membrane was also
evident (Figs. 2C, D, and E, F). We also analyzed the labeling densities
of nNOS, iNOS and eNOS (number of gold particle/μm2) in the
different sub-cellular compartments by counting in 20 representative
cells (Table 1). Morphometric analysis revealed that the number of
gold particles/μm2 in a human monocyte representing nNOS, iNOS
and eNOS were 2.8±0.2, 3.5±0.4 and 5.4±0.2 respectively. The
amount of nNOS labeling in the nucleus (1.8±0.1) was less as
compared to the cytoplasm (4.2±0.3, pb0.001), indicating that most
of nNOS was conﬁned to the cytoplasm, while iNOS and eNOS seems
to be equally distributed in the nucleus and cytoplasm.
3.2.2. nNOS, iNOS and eNOS localization in lymphocytes
NOS intracellular distribution studies in the lymphocyte exhibited
the presence of both constitutive (nNOS and eNOS) and inducible NOS
Fig. 2. nNOS, iNOS and eNOS intracellular distribution in human monocytes. Distribution of NOS isoforms in human monocytes. (A) nNOS labeling in the subcellular compartments:
(i) nucleus (N), (ii) nuclear membrane (NM) and (iii) cytoplasm (Cy). (B) Magniﬁed view of (A) indicating prominent nNOS labeling seen in the nucleus (N) and cytoplasm (Cy) as
shown by arrows. (C) iNOS distribution in nucleus (N), cytoplasm (Cy), nuclear membrane (NM) and plasma membrane (PM). (D) Magniﬁed view of (C) indicating iNOS labeling in
nucleus and cytoplasm. (E) eNOS labeling in the nucleus (N), cytoplasm (Cy), nuclear membrane (NM) and plasma membrane (PM) of human monocyte. (F) Magniﬁed view of (E)
indicating prominent labeling of eNOS in the nucleus and cytoplasm. Bars represent 500 nm (A–F). The image is a representation of at least 3 independent experiments.
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plasma membrane. nNOS was mostly localized in the cytoplasm,
nucleus and adjacent to plasma membrane (Figs. 3A and B). TheTable 1
Labeling densities of NOS isoform (number of gold particles/μm2) in the subcellular
compartments of human monocytes.
Subcellular
compartment
Number of gold particles/μm2in monocytes
nNOS iNOS eNOS
Nucleus 1.8±0.1 3.0±0.5 5.0±0.4a,b
Cytoplasm 4.2±0.3c 4.1±0.5 6.2±0.4d,e
Total 2.8±0.2f 3.5±0.4g 5.4±0.2
Values areMean±SEM. Data were analyzed by one-way ANOVA followed by Newman–
Keul's post analysis test.
a pb0.001 for nNOS in nucleus Vs eNOS in monocyte nucleus.
b pb0.001 for iNOS in nucleus Vs eNOS in monocyte nucleus.
c pb0.001 for nNOS in nucleus Vs nNOS in cytoplasm.
d pb0.001 for eNOS in cytoplasm Vs nNOS in cytoplasm.
e pb0.001 for eNOS in monocyte cytoplasm Vs iNOS in cytoplasm.
f pb0.001 for eNOS Vs nNOS.
g Pb0.01 for eNOS Vs iNOS.presence of iNOS monomers and dimers was seen clearly in the
cytoplasm, nucleus, nuclear membrane and along with the plasma
membrane (Figs. 3C, D, E and F). Morphometric analysis revealed that
the amount of eNOS labeling represented as gold particles/μm2 was
3.6±0.3 (n=20), which wasmore than nNOS (2.6±0.3, pb0.05) but
was similar to iNOS (3.1±0.3) in lymphocytes. Moreover, eNOS
seemed to be equally distributed in nucleus (4.1±0.4) and cytoplasm
(4.2±0.3), while nNOS and iNOS were much more in the cytoplasm
than the nucleus (Table 2).
3.2.3. Distribution proﬁle of NOS isoforms in the monocytes and
lymphocytes
Morphometric analysis exhibited the subtle differences in the
pattern of NOS distribution in the monocyte and lymphocyte
populations. Labeling of nNOS in lymphocytes and monocytes was
comparable, however nNOS labeling was signiﬁcantly more in the
cytoplasm as compared to the monocyte and lymphocyte nuclei
(Figs. 4A and B). iNOS labeling was also almost similar in monocytes
(3.5±0.4) and lymphocytes (3.1±0.3). Distribution of iNOS in the
cytoplasm (4.1±0.5) and nucleus (3.0±0.5) was comparable (Fig. 4A)
in monocytes, while iNOS labeling in the cytoplasm (4.5±0.4) was
Fig. 3. nNOS, iNOS and eNOS intracellular distribution in human lymphocytes. Distribution of NOS isoforms in human lymphocytes. (A) Presence of nNOS protein at different sub-
cellular compartments: (i) nucleus (N) and (ii) cytoplasm (Cy). (B) Magniﬁed view of (A) indicating the presence of nNOS as a dimer in the nucleus and cytoplasm. (C) Sub-cellular
distribution of iNOS in a human lymphocyte: (i) the presence of iNOS in nucleus, (ii) cytoplasm and (iii) plasmamembrane. (D)Magniﬁed view of (C) indicating the presence of iNOS
at the nuclear membrane. (E) Sub-cellular localization of eNOS in (i) the nucleus, (ii) cytoplasm and (iii) plasma membrane. (F) Magniﬁed view of (E) indicating the presence of
eNOS at the nucleus and cytoplasm. Bar represent 500 nm (A–F). The image is a representation of at least 3 independent experiments.
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(Fig. 4B). The presence of eNOS was signiﬁcantly more in monocytes
(5.4±0.2) as compared to lymphocytes (3.6±0.3, pb0.05).Table 2
Labeling densities of nNOS, iNOS and eNOS (number of gold particles/μm2) in the
subcellular compartments of human lymphocytes.
Subcellular
compartment
Number of gold particles/μm2in lymphocytes
nNOS iNOS eNOS
Nucleus 1.6±0.1 2.0±0.3 4.1±0.4a,b
Cytoplasm 4.6±0.9c 4.5±0.4d 4.2±0.3
Total 2.6±0.3e 3.1±0.3 3.6±0.3
Values areMean±SEM. Data were analyzed by one-way ANOVA followed by Newman–
Keul's post analysis test.
a pb0.001 for iNOS in nucleus Vs eNOS in lymphocyte nucleus.
b pb0.001 for nNOS in nucleus Vs eNOS in lymphocyte nucleus.
c pb0.001 for nNOS in nucleus Vs nNOS in cytoplasm.
d pb0.001 for iNOS in nucleus Vs iNOS in cytoplasm.
e pb0.05 for total eNOS Vs total nNOS in lymphocytes.4. Discussion
PBMCs constitute an important component of both vascular and
immune systems. NO essentially inﬂuences both the systems, a
detailed insight into the status of NOS might thus be useful to
understand diverse pathologies involving PBMCs. NO release from
human PBMCs was ﬁrst demonstrated by Salvemini et al. [10], which
was subsequently identiﬁed as a mediator of their microbicidal and
tumoricidal actions, as well as a regulator (enhancer and suppressor)
of T-cell functions [34].
Real time PCR analysis and immunoprecipitation studies indicated
constitutive expression of cNOS and iNOS in PBMCs, monocytes and
lymphocytes. Higher expression of iNOS was found in PBMCs as
compared to eNOS and nNOS (Figs. 1A and B), while monocytes and
lymphocytes expressed more amount of eNOS and iNOS respectively
(Figs. 1D, E and G, H). Number of lymphocytes in PBMCs is muchmore
than monocytes, we therefore detected higher expression of iNOS in
total PBMCs. Existing reports in the literature demonstrate the
presence of iNOS and cNOS transcripts in monocytes obtained from
severe acute pancreatitis patients complicated with systemic inﬂam-
matory response syndrome [36]. Moreover an inverse relationship
Fig. 4. Morphometric analysis for NOS intracellular distribution, represented as bar
diagrams. NOS sub cellular distribution has been shown in the nucleus and cytoplasm of
(A) monocytes and (B) lymphocytes. Results have been expressed as Mean±SEM of
the number of gold particles/μm2 (**pb0.001). The data is a representation of at least 3
independent experiments.
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cytes, macrophages and monocytic cell lines upon stimulation with
LPS/IFN-γ [37]. Upregulation of iNOS in monocytes from pulmonary
tuberculosis patients have also been reported [38]. Germinal center T
cells and follicular dendritic cells did not express eNOS mRNA. The
presence of eNOS protein was however conﬁrmed in T cells from
peripheral blood and in various germinal center cells of frozen
tonsillar sections [9]. Thyroid hormones upregulate iNOS gene
expression downstream to PKC-zeta in murine tumor T cells [39]. T
cell activation induces formation of reactive oxygen intermediates
and Ca+2-dependent NO production [35]. Understanding of the
differential regulation of NOS expression, catalysis and intracellular
localization in PBMCs might be helpful to evolve strategies against
graft versus host responses following transplantation, tumor surveil-
lance, inﬂammation and infectious diseases. The present multi-
parametric study is the ﬁrst step in this direction, which demonstrat-
ed relative prevalence of NOS isoforms at the transcript and protein
levels by real time PCR and immunoprecipitation respectively, NO
generation capabilities and NOS sub-cellular distribution in PBMCs,
monocytes and lymphocytes. Results obtained by real time PCR and
IP/WB indicated the differences in NOS ratio to β-actin (106 folds in
the case of real time PCR and 25 folds in IP/WB). This could be due to
the differences in the sensitivity of the methods used, mRNA stability
or protein degradation, which needs to be ascertained in PBMC
subsets under physiological and pathological conditions.
NO derived from NOS in human mast cells regulate leukotriene
production [14]. Yip et al. [40] have demonstrated the inducible
expression of eNOS and iNOS in human mast cells following TNFα,
IFNγ and IL1β stimulation. Role of NOS in regulating deformability of
human RBC membrane and inhibition of platelet activation has also
been proposed [41]. Such studies might be helpful in ascertaining the
importance of NO/NOS in PBMCs.The relative catalytic potential of the calcium dependent and
independent NOS in PBMC lysates was almost similar, that was
contrary to the relative abundance of iNOSmRNA and protein (Figs. 1A
and B). This discrepancy could arise from an inhibitory regulation
imposed over the avid production of NO from iNOS despite its
constitutive presence. Inhibitory protein–protein interactions with
iNOS involving caveolin [23], kalirin, or PIN might exert an inhibitory
effect on iNOS activity, which remains to be ascertained in PBMCs.
Speculatively iNOS in PBMCs might have non-catalytic roles such as
trafﬁcking of cargo proteins to intracellular locales as is demonstrated
for nNOS [42] or itmight be sequestered in the perinuclear aggresomes
[43]. A subset of human iNOS could be sensitive to oscillations in the
intracellular calcium reserve thus contributing to both calcium
dependent and independent catalysis as has been shown in guinea
pigs [44],whichwarrants further investigations. It has been shown in T
lymphocytes that NO synthesis can be triggered by acetylcholine
mediated augmentation in [Ca+2]i dependent NOS activity [45]. It is
thus worthwhile to explore the physiological regulators of NOS
catalysis governing the extent of NO generation from the calcium
dependent and independent isoforms in PBMC subsets.
NOS catalysis could also be inﬂuenced by its distinct subcellular
localizations, which vary in terms of pH, immediate microenviron-
ment, presence of negative and positive protein regulators, substrate
and cofactors availability. Controlled NO generation at the subcellular
locales and organelles might be of importance in terms of adequate
amount of NO generation at the right place so as to play a pivotal role
in modulating organelle speciﬁc functions. Biological actions of NO,
either beneﬁcial or detrimental are largely concentration dependent
and transient due to shorter half life of NO. Characteristically NO
liberated from iNOS quickly attains critical concentration and has
been implemented in the cytotoxic actions [46]. nNOS and eNOS
however generate a low amount of NO that gradually builds up inside
the organelles. NOS could also have non-catalytic attributes in sub-
cellular locales which is a vastly unchartered area of research. The
present study explored the relative nucleo-cytoplasmic distribution of
NOS isoforms in resting human PBMCs by immunoelectron micros-
copy. The technique used is not considered suitable to assess the
quantitative status of protein expression due to exhaustive and time
taking steps involved in the sample preparation, which might lead to
protein degradation, on the other hand it is also understandable that
the distribution of protein might not be similar at all the planes in cell
sections. This may partly account for the lack of correlation between
relative abundance of iNOS as seen at transcript and protein levels
with morphometry data in the lymphocytes. NOS was present in the
cytoplasm, nucleus, nuclear membrane and plasma membrane in
monocytes and lymphocytes (Figs. 2A–F and Figs. 3A–F). Most of the
NOS isoforms were conﬁned to cytoplasm but considerable labeling
was also evident in the nucleus of monocytes and lymphocytes.
Functional importance of the sub-cellular localization of NOS isoforms
however remains to be identiﬁed in PBMCs. Morphometric analysis
revealed that eNOS was more than nNOS and iNOS in the monocytes.
The subtle differences seen in the NOS distribution might be
important for the cell/organelle speciﬁc functions being regulated
by the NO availability and remain to be explored. NOS isoforms
interact with a wide array of scaffolding proteins, positive and
negative catalytic regulators, signaling intermediates to membrane
receptors which might affect both its trafﬁcking and NO generation
potential [4]. nNOS having PDZ domain interacts with several other
PDZ domain containing proteins. Western blot analysis with anti-
bodies speciﬁcally directed against the N-terminal region of nNOS
which bears the PDZ domain encoded by exon 2, revealed a full length
nNOS protein of 160 kDa in the PBMCs (Fig. 1B). iNOS and eNOS in
PBMCs were also full length proteins of 130 kDa. Based on our
observations, future endeavors need to be directed to assess the
relative expression of NOS isoforms, their subcellular localization,
trafﬁcking, nitration and nitrosylation of important proteins in
1707R. Saluja et al. / Biochimica et Biophysica Acta 1813 (2011) 1700–1707different pathological conditions where PBMCs play an active role in
disease onset and progression.
The present study convincingly demonstrates the presence of
functional NOS isoforms, their expression and the differential pattern
of subcellular distribution in human PBMCs, monocytes and lympho-
cytes. The information furnished herein is likely to serve as a template
for the future studies directed towards understanding NOS and NO
mediated signaling events in various hereditary and acquired
immune/inﬂammatory disorders associated with distinct subpopula-
tions of PBMCs.
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